• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b

tetano

Editor, Senior Moderator
Vaccine


. 2022 Mar 29;S0264-410X(22)00369-3.
doi: 10.1016/j.vaccine.2022.03.057. Online ahead of print.
Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination


Hideaki Kato[SUP] 1 [/SUP], Kei Miyakawa[SUP] 2 [/SUP], Norihisa Ohtake[SUP] 3 [/SUP], Yutaro Yamaoka[SUP] 4 [/SUP], Satoshi Yajima[SUP] 5 [/SUP], Etsuko Yamazaki[SUP] 5 [/SUP], Tomoko Shimada[SUP] 6 [/SUP], Atsushi Goto[SUP] 7 [/SUP], Hideaki Nakajima[SUP] 8 [/SUP], Akihide Ryo[SUP] 9 [/SUP]



Affiliations

Abstract

To evaluate vaccine-induced humoral and cell-mediated immunity at 6 months after completion of two doses of BNT162b2 vaccination, immunoglobulin G against SARS-CoV-2 spike protein (SP IgG), 50% neutralizing antibody (NT[SUB]50[/SUB]), and spot-forming cell (SFC) counts were evaluated by interferon-γ releasing ELISpot assay of 98 healthy subjects (median age, 43 years). The geometric mean titers of SP IgG and NT[SUB]50[/SUB] decreased from 95.2 (95% confidence interval (CI) 79.8-113.4) to 5.7 (95% CI 4.9-6.7) and from 680.4 (588.0-787.2) to 130.4 (95% CI 104.2-163.1), respectively, at 3 weeks and 6 months after the vaccination. SP IgG titer was negatively correlated with age and alcohol consumption. Spot-forming cell counts at 6 months did not correlate with age, gender, and other parameters of the patients. SP IgG, NT[SUB]50,[/SUB] and SFC titers were elevated in the breakthrough infected subjects. Although the levels of vaccine-induced antibodies dramatically declined at 6 months after vaccination, a certain degree of cellular immunity was observed irrespective of the age.

Keywords: 50% neutralization titer; Cell-mediated immunity; Coronavirus disease-2019; Interferon-γ releasing ELISpot assay; Vaccination; Variant of concern.
 
Back
Top Bottom